Evaluating the effects of injectable Niagen®+ compared to NAD+ for healthy aging
Official title: Absorption and Tolerability of Injectable Administration of Niagen®+, Nicotinamide Riboside Chloride, a Specialized Form of Vitamin B3, as Compared to NAD+: a Double Blinded, Randomized, Controlled Clinical Trial
Run by Nutraceuticals Research Institute · NCT06919328 · Data updated 2026-11-12
This study is testing if an injectable form of vitamin B3 called Niagen®+ is safe and effective for healthy aging compared to another treatment called NAD+ in healthy adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 65 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Nutraceuticals Research Institute Academic / other |
| Locations | 1 site (Huntsville, Alabama) |
| Status | Recruiting |
| Started | October 31, 2024 |
| Main results expected | April 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | April 9, 2025 |
| Trial ID | NCT06919328 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults aged 40-65 with a BMI of 25-34.9 and a sedentary lifestyle.
✕Probably not a fit
Patients with current diagnoses of seizure disorders, diabetes, or significant kidney or liver issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the tolerability and subjective effects of Niagen®, a specialized form of vitamin B3, administered through intramuscular, subcutaneous, and intravenous-push routes in healthy adults. It compares these effects to those of NAD+, an active comparator, using the same administration methods. Participants will be monitored for their responses to the injections to determine the safety and acceptability of Niagen®+. The study aims to gather data that could inform future applications of NAD+ precursors in promoting healthy aging.
Why it matters
Potential benefit: If successful, this study could provide insights into effective methods for enhancing healthy aging through improved NAD+ levels.
How similar studies have gone: While the specific administration of Niagen®+ is novel, similar studies on NAD+ precursors have shown promising results in enhancing health outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study * Lives within 100 miles of the NRI study site * Any gender, aged 40-65, inclusive * Good general health as evidenced by medical history * BMI 25-34.9 kg/m2 * Sedentary behavior (defined as \<20 minutes per day or 100 minutes per week of moderate to vigorous exercise) * Demonstrated fatigue (Fatigue Assessment Scale) defined as a below-average score * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study * Agreement to adhere to Lifestyle Considerations throughout study duration Exclusion Criteria: * Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease * ANY chronic illness (pre-disease state acceptable) * Out of range phosphate levels at baseline * BMI less than 25 or greater than or equal to 35 * Pregnancy, trying to conceive, or breastfeeding * Known allergic reactions to any components of the intervention or related compounds, including any form of B3 * Positive COVID-19 test within 30 days of the study period * Recent dramatic weight changes (10% change in body weight in the last 6 months) * Existing usage of a NAD+ or NAD precursor supplement in any form (oral, nasal, patch, or injection/IV administration), including a B-complex supplement, within 60 days of the study, not including multivitamins. * Introducing a new medication, supplement, investigational drug, or other intervention (including lifestyle changes) within 60 days of the start of the study.
Where it's running
-
Nutraceuticals Research Institute
Huntsville, Alabama, United States Recruiting
Study contacts
- Study coordinator: JESSIE HAWKINS, PhD
- Email: j.hawkins@nutraceuticalsresearch.com
- Phone: 2562039010
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.